Last reviewed · How we verify
Yellox
Yellox is a Small molecule drug developed by University of Trieste. It is currently in Phase 3 development for Pain, Post-Op Ocular Inflammation, Postoperative Ocular Pain. Also known as: Bromfenac 0.09 % Ophthalmic Solution.
Yellox is a brand name for bromfenac, a nonsteroidal anti-inflammatory drug (NSAID) used for the treatment of ocular inflammation and pain. It is a small molecule cyclooxygenase inhibitor, marketed for short-term, local use in the treatment of various eye conditions, including macular edema, cystoid macular edema, and cataract.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Yellox |
|---|---|
| Also known as | Bromfenac 0.09 % Ophthalmic Solution |
| Sponsor | University of Trieste |
| Target | Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 3 |
Approved indications
- Pain
- Post-Op Ocular Inflammation
- Postoperative Ocular Pain
Common side effects
- Abnormal sensation in eye
- Conjunctival hyperemia
- Eye irritation
- Eye pain
- Eye pruritus
- Eye redness
- Headache
- Iritis
Key clinical trials
- Bromfenac Versus Dexamethasone After Cataract Surgery (PHASE4)
- Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery (PHASE4)
- Effectiveness of Periocular Drug Injection in CATaract Surgery (PHASE3)
- PGE2 Levels in Patient Treated With NSAIDs (PHASE3)
- PRevention of Macular EDema After Cataract Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Yellox CI brief — competitive landscape report
- Yellox updates RSS · CI watch RSS
- University of Trieste portfolio CI
Frequently asked questions about Yellox
What is Yellox?
What is Yellox used for?
Who makes Yellox?
Is Yellox also known as anything else?
What development phase is Yellox in?
What are the side effects of Yellox?
What does Yellox target?
Related
- Target: All drugs targeting Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase
- Manufacturer: University of Trieste — full pipeline
- Therapeutic area: All drugs in Pain
- Indication: Drugs for Pain
- Indication: Drugs for Post-Op Ocular Inflammation
- Indication: Drugs for Postoperative Ocular Pain
- Also known as: Bromfenac 0.09 % Ophthalmic Solution
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing